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ABSTRACT 
Epigenetic   alterations   and   aberrant   expression   of   genes   controlling   epigenetic 
mechanisms have been identified in several cancers, including medulloblastoma and 
glioma, the most common primary brain tumors in children and adults, respectively. 
We have been investigating if combination therapy using histone deacetylase inhibitors 
(HDACi) and receptor tyrosine kinase inhibitors (RTKi) will enhance glioblastoma and 
medulloblastoma cell killing. In medulloblastoma studies we combined a DNA 
methylation inhibitor, an HDAC inhibitor together with tyrosine kinase inhibitors. 
 
In the first study (Paper  I) we have shown that combining  HDACi  with the RTKi 
gefitinib  and  vandetanib  resulted  in  enhanced  cell  killing  and  reduced  clonogenic 
survival. Mono-therapy using HDACi sodium 4-PB induced minor cell killing effects 
in neither of the analyzed cell lines. Similar results were observed after mono-therapy 
using gefitinib or vandetanib. However the combination of 4-PB with gefitinib resulted 
in significantly increased cell death compared to mono treatment in both cell lines. 
Furthermore, the double therapy resulted in a significant decrease in colony formation. 
 
The second study (Manuscript) showed that combination of drugs that inhibit two of 
the most important epigenetic factors (gene methylation and post-translational 
modifications of protein histone-associated DNA with small molecule inhibitors of 
receptor tyrosine kinase) enhances cell killing in two medulloblastoma cell lines. The 
HDACi, 4-phenylbutyrate (4-PB) and the demethylation agent, 5-Aza-2’deoxycytidine 
(5-Aza-dC) had minor effects on medulloblastoma cell cytotoxity when used as single 
agents. A significant enhancement in cell cytotoxity was seen when these drugs were 
combined with imatinib or sorafenib. Triple combinations resulted in accumulation of 
cells with subG1 DNA content and were associated with a decrease in the expression of 
histone deacetylase genes and reduced global methylation. This occurred together with 
an increase in apoptosis. 
 
Taken together these results suggest that combinations of these drugs may be beneficial 
in the treatment of medulloblastoma. 
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1  THESIS SUMMARY 
 
 
1.1   BRAIN TUMORS 
 
 
1.1.1   Adult  Brain  Tumors 
 
Brain tumors in both adults and children are among the most deadly diseases in human 
despite the recent increase in biological understanding and management of the diseases. 
Hence, there is a great need for further investigation and development of new therapeutic 
modalities. Current therapeutic techniques need to be improved, both in order to cure 
more patients and to reduce secondary effects [1]. 
According to the American cancer society there is a higher incidence of brain tumors in 
men than in women 7.6 vs 5.3 respectively, and the age peaks between 65 and 79 years 
[2]. 
There are many different types of brain tumors in adults (fig 1). Among these, gliomas 
are most frequent accounting for 70% malignant brain tumors [3]. The most severe 
subtype of gliomas, glioblastoma multiforme accounts for 50% (20% of all adult brain 
tumors) of diffuse gliomas [3]. Glioblastoma is more common to occur in white persons 
than in black persons [2]. 
Gliomas are divided into four groups according to the World Health Organization grade I 
and grade II are low grade where grade III and grade IV are high grade gliomas, the most 
common glioma is glioblastoma multiforme [2, 3]. Treatment for gliomas requires 
surgery, radiation, and chemotherapy [2, 3]. 
 
 
 
 
 
 
 
Figure  1 Graph representing  % of adult brain 
tumor types (statistics taken from the ABTA) 
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1.1.2   Pediatric Brain  Tumors 
 
Although brain tumors are rare in children, pediatric brain tumors are the most common 
solid cancers of childhood representing 25% of all pediatric cancer cases, and the 
leading cause of death due to disease in western countries [4]. 
According to the USA Central Brain Tumor Registry (CBTRUS) the annual incidence 
of pediatric brain tumors between the ages of 0-19 years is of 4.84 per 100.000 
population [4]. There are different types of pediatric brain tumors (fig 2): gliomas, 
astrocytomas, ependimomas, embryonal tumors (medulloblastoma), Choroid plexus 
tumors, germ cell tumors, and craniopharyngiomas, the therapy for these tumors 
requires surgery followed by radiation and chemotherapy [4]. 
Medulloblastoma (MB) is the most common form of pediatric brain cancer accounting 
for 15% of all CNS cases [5]. 
Even though current therapeutic protocols have improved the overall survival of 
patients, there is a need to develop new therapeutic modalities for medulloblastoma, 
since the current therapies often cause long-term side effects with high risk of severe 
morbidity even if cured from the tumor. 
In summary primary brain tumors of adults and children need to be further investigated 
to achieve a better understanding of these tumors that can help to develop new therapies, 
improve survival and quality of life for the patients. 
 
 
 
 
 
 
 
 
 
 
Figure 2 Types of pediatric brain tumors 
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1.2   MEDULLOBLASTOMA 
 
Medulloblastomas are a compilation of molecular and clinical diverse tumor types that 
together encompass the most frequent malignant brain tumors in children [6]. The 
majority of medulloblastomas arises in the cerebellum and are usually diagnosed before 
the age of 10 years [5, 7]. Medulloblastomas are currently classified according to five 
histological subtypes: desmoplastic/nodular, classic, large cell, medulloblastoma with 
extensive nodularity (MBEN) and anaplastic medulloblastoma [7-9].  Classic 
medulloblastoma is the most common variant followed by desmoplastic [7]. Risk 
stratification of patients diagnosed with MB is based on patient age, surgical tumor 
resection, presence of metastasis and histology (presence or absence of diffuse 
anaplasia). Based on these parameters patients are classified as standard risk patients, 
who are older than 3 years, with localized disease, without anaplasia, and all the rest are 
considered as high risk [8]. 
 
 
1.2.1   Medulloblastoma Origin 
 
Different subtypes of medulloblastoma have distinct cellular origins. One subtype 
originates from cerebellar granule neural precursor (GNP) cells located in the external 
granular layer (EGL) of the cerebellum as a result of aberrant Shh signalling [10, 11]. A 
subpopulation of cells from these tumours is positive for the progenitor markers Math1 
and CD15 [12]. A different medulloblastoma subtype arises outside the cerebellum from 
cells of the dorsal brainstem and is dependent on Wnt signalling. These tumours contain 
aberrantly proliferating Zic (+) precursor cells [13]. Finally, a third medulloblastoma 
subtype deriving from prominin1-positive (Prom1) cerebellar stem cells has been 
proposed. These tumours contain elevated Myc expression [14, 15]. 
 
Abnormal activation of the developmental signalling cascades Shh and Wnt is observed 
in approximately half of all medulloblastomas. Also, Notch, ERBB2, PI3K/Akt and 
TGFf3 signalling has been shown to contribute to the development of medulloblastoma. 
[16-18]. 
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1.2.2    Molecular Subgroups of Medulloblastoma 
 
Medulloblastomas have recently been stratified into four distinct molecular subgroups 
based on transcriptional signatures, mutational spectra, copy number profiles and 
clinical features. These groups have been named: WNT, sonic hedgehog (SHH), group 
3 and group 4 (fig 2) [19]. The different subgroups are briefly described below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3 Representation of medulloblastoma subgroups 
 
 
 
1.2.2.1   Sonic Hedgehog (SHH) 
 
Sonic hedgehog (SHH) is a morphogenic factor that has been shown to be in control of 
central nervous system progenitor’s proliferation. It is known that SHH acts on gene 
expression through the activity of a transcription factor family of proteins called GLI. 
When SHH is absent the transmembrane receptor Patched 1 will inhibit the seven-pass 
transmembrane protein Smoothened (SMO), preventing its translocation to the 
primary cilia [20]. Aberrant expression of key proteins in the SHH signal transduction 
pathway may lead to tumorgenesis and tumors classified in the SHH subgroup have 
been shown to develop from cerebellar granular progenitors (GCPs) [21, 22]. 
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Approximately 25% of MBs originate from GNP due to the aberrant alteration of SHH 
pathway [13]. SHH pathway is directly connected to the cell cycle control and the 
induction of cyclins D1 and D2 through the mediation of MYCN [18]. MYCN acts 
downstream of the SHH pathway and its expression has been seen in both nodular and 
anaplastic MBs. Patients with nodular type of MB have a better survivor rate than those 
with anaplastic [23]. 
Desmoplastic/nodular tumors belong to the SHH subgroup. These tumors are found 
mainly in infants and adults and account for more than 60% of patients from either 
group [24]. The MBEN subtype is seen mainly in very young infants and has a 
relatively poor prognosis. It has been liked to Gorlin syndrome an autosomal dominant 
disorder that exhibits germline mutations in the SHH receptor Patched [24]. 
 
 
1.2.2.2   WNT 
 
WNT tumors develop outside the cerebellum possibly from cells of the dorsal 
brainstem and differ from SSH tumors [13]. Publishes series has shown that the genes 
marking this subtype are highly expressed at the lower rhombic lip (LRLPs) [25]. 
Deregulations of the WNT signaling pathway occur in about 10-15% of 
medulloblastomas. The activation of the WNT pathway occurs when Wnt binds to the 
seven transmembrane receptor Frizzled [21]. Frizzled activates the Disheveled protein 
resulting in inhibition of the destruction complex and translocation of f3-catenin from 
the cytoplasm to the nucleus. In the nucleus f3-catenin interacts with members of the T 
cell factor/lymphoid enhancer factor (Tcf/Lef) family of transcription factors and 
activation of target genes such as cyclin D1 and c-Myc [21].  Tumors in this subgroup 
have a classic histopathology, and it affects older children [26]. 
 
1.2.2.3   Group 3 
 
The majority of tumors seen in this subgroup are mostly large cell/anaplastic. Like WNT 
tumors, subgroup 3 tumors present a high expression of MYC and the amplification of 
MYC influences patients survival [19, 27]. The majority of patient with group 3 tumors 
are males, and it occurs in both infants and older children [19, 26]. Investigation has 
showed that the highest frequency of metastatic MB falls into this subgroup (30%) and 
also into subgroup 4 (31%) [27]. 
 
 
1.2.2.4   Group 4 
 
Tumors classified as group 4 are large cell/anaplastic MB. This is the only group of 
tumors that does not present high expression of any member of the MYC family [24, 
27]. Like WNT tumors most of the patients are between the ages of 9 and 10 years at 
the time of diagnosis [19, 24, 27]. The presence of isochromosome 17q is quite high in 
this sub-group of MB (66%) [27]. There is not much known of this group and no animal 
models have been developed to further investigate its pathogenesis. 
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1.3   EPIGENETICS IN MEDULLOBLASTOMA 
 
 
Epigenetics are modifications of the DNA or associated proteins, other than DNA 
sequence variation, that carry information content during cell division [28]. DNA 
methylation and histone modifications are coordinately regulated processes which 
regulate the cell-specificity of intracellular signalling, the two processes are intimately 
involved in the epigenome together with acetylation, methylation, and phosphorylation 
[28, 29]. 
Epigenetic alterations are early events in the loss of cellular homeostasis. A deeper 
general understanding of the epigenetic mechanisms and patterns will provide a 
foundation for the future clinical therapy of MB and other types of pediatric and adult 
tumors. Researchers have shown epigenetic events to be involved in medulloblastoma 
development by promoter methylation [30]. 
The WNT signalling pathway is activated due to epigenetic events, which lead to the 
inactivation of SFRP and DKK, which enable β-catenin to translocate to the nucleus 
switching on WNT signalling [31]. 
Mutations in many genes involved in chromatin remodeling complexes have been 
shown, some of these genes are MLL2, GPS2, KDM6A, BCOR, SMARCA4 [32]. 
Among the genes found to suffer mutations in group 4 tumors are the MLL3 and 
HDAC2, the two genes are involved in histone modifications [32]. A study performed 
by Parsons DW et. al. in a study of 22 MB tumors revealed common inactivation 
mutations of the MLL2 and MLL3 in 16% of the tumors.[33, 34] 
Recent research of the Bmi1 signaling pathway, has showed that its deregulated in MB 
[35]. 
The Bmi1gene a member of the chromatin Polycom-group recently proven to be a 
regulator neural stem cells via the p16Ink4a and p19Arf pathways, seems to also play a 
role as an epigenetic regulator of fate in normal cells and has been implicated in MB 
development [35]. 
 
 
 
1.4   CURRENT THERAPY FOR MEDULLOBLASTOMA 
 
The current therapeutic protocol for medulloblastoma includes multimodal therapy, 
surgery, radiation therapy and chemotherapy. The treatment is based on risk assessment 
based on the age of the patient, infants (<3 years) have a pored outcome and are 
classified as high risk these patient are treated only with chemotherapy. Patients older 
than 3 years receive radiation therapy after tumor recession followed by adjuvant 
chemotherapy[36].  Patients older than 3 years that belong to high risk group are treated 
with higher radiation dosage and adjuvant chemotherapy. 
Tumor recession is of great importance in risk stratification if the tumor is recess 
completely than the patient will fall into average outcome and low risk, if the tumor can 
only be partially recessed than the patient will fall into a high risk pored outcome group 
[37, 38]. Based on these classifications the therapeutic modality will be decided [37- 
39]. 
Commonly therapeutically modalities for low and high risk patients include cisplatin; 
N-(2-chloroethyl)-N_-cyclo-hexyl-N-nitrosurea (CCNU); vincristine; etoposide and 
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cyclophosphamide [36, 37]. Craniospinal radiation in average risk patients is of 23.4 
Gy craniospinal and 54 Gy radiation of the posterior fossa, high risk patients receive 
36 Gy craniospinal radiation followed by 54 Gy radiation of the posterior fossa [36, 
39]. 
New therapeutic strategies are been investigated, that will include the use of proton 
radiation and different combination of therapeutic agents, such as target molecules 
and epigenetic modifiers [36, 39]. 
To avoid the risks of developing secondary malignancies, and learning disabilities, and 
organ damage , research is been focuses on proton therapy [40]. 
 
 
 
1.4.1   Therapy  Resistance 
 
This is one of the biggest drawbacks in medulloblastoma and cancer therapy in general. 
Many patients develop resistance after treatment has started and others might never enter 
remission. Patients can develop resistance not only to drug therapy but also to radiation 
therapy. 
It is believe that resistance to therapy is multifactorial and it involves a number of 
factors such as autocrine/paracrine signaling which involves the local tumor 
microenvironment; loss of therapeutic target and other factors [41]. A loss of response 
to therapies has been attributed to an attenuation of cancer death pathways (apoptosis); 
which can occur due to suppression of cell cycle arrest/apoptosis cascades [41]. 
Recently research has shown how resistance can be overcome in the treatment of 
medulloblastoma and other forms of pediatric brain tumors with the use of epigenetic 
drugs [18, 42]. For instance it has been shown how promoter hypermethylation can 
modulate cancer sensitivity to drug and radiation therapy [43]. A specific predictive 
biomarker of tumor response to therapy is O6-methylguanine DNA methyltransferase 
(MGMT), it has been shown that MGMT promoter methylation can be use to predict 
glioblastoma response to alkylating agents [43]. Adults whose tumors have an MGMT 
deficiency have shown to have a better outcome to alkylator chemotherapy [44].  In 
medulloblastoma studies have shown that one way to overcome MGMT mediated 
chemo resistance could be by depletion of MGMT [45]. 
Epigenetic modulators (HDACi) have recently been shown to overcome resistance to 
drug therapy, the mechanism by which HDACi excerpt their action has not been 
elucidated but some investigators think it might be through the hyperacetylation of 
histones after treatment with an HDACi [46, 47]. 
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1.5   HDAC INHIBITORS, DNMT INHIBITORS AND RECEPTOR TYROSINE 
KINASE INHIBITORS AS PRIMARY MB TARGETS 
 
 
1.5.1   Histone deacetylase inhibitors 
 
 
The most studied histone modifications are acetylation of lysines. This is an important 
process in the regulation of gene expression and involves histone deacetylases (HDACs) 
and histone acetyl transferases (HATs) [28, 48]. HDACs have been divided into 4 
different classes. Class I HDACS (1, 2, 3 and 8). Class II is subdivided into two classes: 
class IIa HDACs (4, 5, 7, and 9), class IIb HDACs (6 and 10). Class III are named 
sirtuins and these enzymes differ from the class I II and IV in that their function is 
NAD-dependent. Class IV includes HDAC11 [49, 50]. 
Inhibitors of HDACs, HDACi are potent inducers of differentiation and apoptosis by 
shifting the equilibrium of acetylation and deacetylation in favour of acetylation of core 
histones. 
HDAC inhibitors activated either one or both apoptotic cell death pathways (intrinsic 
and extrinsic pathways) [51, 52]. 
An example of a non-toxic HDACi is sodium 4-phenylbutyrate (PB) – an aromatic 
fatty acid which can reach biologically active serum borders in the mM levels, with oral 
administration. PB has been evaluated in medulloblastoma cell lines where it increased 
acetylation of histones, with subsequent differentiation effects [53, 54]. PB can induce 
cell cycle arrest, involving induction of p21Waf1 in G1 and G2, and induce 
differentiation or apoptosis in a wide range of cell types [54]. Among the varieties of 
HDACi:s, valproic acid and Sodium butyrate, are two other short chain fatty acids that 
have been reported to be well tolerated by patients [50]. These drugs have a very short 
life time in plasma and therefore, high dosages are required in order to achieve good 
therapeutic effects [50, 55, 56]. The hydroxamic acids Trichostatin A (TSA) and 
suberoylanilide hydroxamic acid (SAHA) on the other hand, have high therapeutic 
effects at nanomolar concentrations [54-56]. SAHA has been reported to down regulate 
the expression of the ErbB family [55]. 
HDACi induce downregulation of anti-apoptotic proteins and upregulation of pro- 
apoptotic proteins [55]. HDACi have also been shown to inhibit medulloblastoma cell 
growth, induce cell death and enhance the therapeutic effects of ionizing radiation (IR) 
[56]. One advantage of HDACi is their induction of cancer cell death, while normal 
cells are relatively in-sensitive to the drugs [54]. 
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However, HDACs are also involved in the deacetylation of non-histone proteins, and 
transcription factors [57]. There is a lot of research focusing on the deacetylation of 
non-histone proteins since they are known to play a big role in cancer progression and 
development due to aberrant alterations involving HDACs [58]. Further research on 
HDACs will aid in the development of new and more specific HDAC inhibitors for the 
treatment of cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Pathways affected by HDACi 
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1.6   DNA METHYL TRANSFERASES INHIBITORS 
 
The occurrence of epigenetic silencing during tumor development can be exploited by 
using epigenetic drugs to potentiate chemo sensitivity and response of the tumor to 
chemotherapeutic drugs [59]. Tumors show an increased methylation of CpG islands 
leading to gene silencing, since these regions often are associated with gene promoters 
[59]. 
DNA methylation is the enzymatic addition of a methyl group in the fifth position of the 
cytosine ring in the CpG dinucleotide context [59, 60]. The enzymes catalysing this 
enzymatic addition are the DNA methyltransferases (DNMTs) using the methyl donor 
S-adenosylmethionine (SAM). The products are 5-methylcytosine (5meC) and S- 
adenosylhomocysteine  [60, 61]. There are three enzymatically active isoforms of 
DNMTs; which methylates cytosin; the de novo methyltransferase DNMT1, and the 
maintenance methyltransferases DNMT3a, DNMT3b, [62, 63]. 
The two DNMTs inhibitors decitabine (5-Aza-2’deoxycytidine) and azacitidine (5- 
azacytidine) are currently under clinical trials for solid tumors after their success in the 
treatment of MDS and AML. Both are cytidine derivatives, and are incorporated into 
DNA where they bind and lock the DNA methyltransferase [62, 63].  The two 
compounds are now in phase II clinical trials for solid tumors, in monotherapy as well 
as in combination with HDACi [62, 63]. 
Both decitabine and azacitidine are incorporated into DNA that causes an irreversible 
inactivation of DNMTs, which results in the reactivation and expression of tumor 
suppressor genes that previously had been aberrantly silenced by DNA methylation 
[64]. Research studies of haematological malignancies have shown that in bone marrow 
mononuclear cells previously collected from patients with MDS in a phase II study 
with decitabine silenced tumor suppressor genes had been reactivated [64]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Represents rational of epigenetic combination targeting 
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1.6.1   Combination of DNMT and HDAC Inhibitors 
 
 
The cytotoxicity of the DNMT inhibitors can be dramatically reduced when they are 
administered in combination with HDACi since the effective dosages are lowered [62, 
63, 65]. In addition, clinical trials for triple negative metastatic breast cancer (lack of 
expression of the estrogen and progesteron receptors, and the Her2/neu) have 
demonstrated that combined administration of DNMTi and HDACi to patients before 
treatment with tamoxifen (an antagonist of the estrogen receptor) has resulted in the 
restoration and tamoxifen sensitivity of the estrogen receptor (ER) [63, 65]. The ER is 
silenced by methylation and histone deacetylation in this type of cancer, and therefore 
by reverting these epigenetic alterations the ER becomes active and the patients 
respond to therapy [63, 65, 66]. Combination therapy using DNMT and HDAC 
inhibitors in 
solid tumors is promising, since it restores gene activities that have been epigenetically 
silenced, making the gene products responsive to targeting drugs. However the 
selection of epigenetic modifiers to be incorporated in cancer therapy should be based 
on the epigenetic profile of the tumor. 
Due to the promising effects seen by their use during adult solid tumor therapy, the 
combination of epigenetic therapies is a promising therapeutic strategy for the 
treatment of metastatic aggressive pediatric cancers. 
 
 
 
1.6.2   Receptor tyrosine kinase  inhibitors 
 
Current therapy for MB includes the use of cytotoxic agents that interfere with cell 
division and result in cell death. Molecular target drugs act by targeting specific 
aberrant features of the cancer cell. The identification of MB subgroups will enable 
clinicians to include molecular target drugs into the therapeutic protocols for MB 
therapy. Drugs in such clinical studies should be selected according to the molecular 
characteristics of the different tumor subgroups. The large number of novel drug 
candidates also offers the possibility of multiple targeting. 
 
RTKs are a large family of enzyme-linked surface receptors that interact in order to 
form a complex signalling network [67, 68]. Some members of this class of surface 
receptors are the epidermal growth factor receptor (EGFR), the platelet derived growth 
factor receptors (PDGFRs) and the vascular endothelial growth factor receptors 
(VEGFRs). All these receptors have been implied in pediatric cancers, including 
medulloblastoma, where they potentially contribute to tumor cell growth and to 
angiogenesis [67, 68]. 
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1.6.2.1   EGFR 
 
The EGFR receptor is over-expressed in many types of cancer and has also been 
reported to be expressed in MB [69]. 
Additional members of the EGFR-family are erythroblastic leukemia viral oncogene 
homolog 2 (erbB2), erythroblastic leukemia viral oncogene homolog 3 (erbB3), and 
erythroblastic leukemia viral oncogene homolog 4 (erbB4), which are also expressed 
in medulloblastoma [23, 70]. 
Medulloblastoma expresses high levels of ErbB-2, whereas in the normal cerebellum 
the ErbB-2 level is undetectable [68, 71]. The ERBB2 is a marker for survival and has 
recently been pointed as a marker for poor prognosis [72, 73]. 
 
Gefitinib (Iressa)  and Erlotinib (Tarceva) are the first approved inhibitors of the 
EGFR.  Gefitinib is in clinical trial for the treatment of diffuse intrinsic pontiac gliomas 
(DIPG), an aggressive form of pediatric brain tumor and has been assessed for the 
treatment of medulloblastoma [68, 74-76]. 
Gefitinib was also in clinical trials for pediatric gliomas where studies have 
demonstrated that aberrant overexpression of the EGFR is responsible for cell 
proliferation [77]. 
 
 
1.6.2.2   PDGFR 
 
The PDGFR family comprises two members; the PDGFRA and PDGFRB [70, 78, 79] . 
This receptor also signals through a surface receptor, and has been implicated in MB 
development [78, 80]. The PDGFRA and PDGFRB are upregulated in metastatic forms 
of MB [36, 81, 82]. Their expression has been associated with pored survival [36]. 
 
Imatinib (Gleevec) an inhibitor of the PDGFRa and f3 receptors; the ABL; BCR-ABL; 
KIT and CSF-1R, it has been tested in clinical trials for medulloblastoma [74, 83]. 
Imatinib showed excellent results during clinical trials against gastrointestinal stromal 
tumors (GIST), that show a high expression of KIT, and mutations of the PDGFRA [84]. 
Some forms of metastatic MB tumors have an overexpression of KIT besides 
upregulation of the PDGFRA and PDGFRB [85]. 
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1.6.2.3   VEGFR 
 
receptor-1; vascular endothelial growth factor receptor-2; and vascular endothelial 
growth factor receptor- 3, which regulate angiogenesis after activation by members of 
the vascular endothelial growth factor family. 
Several VEGFR inhibitors have undergone and are currently undergoing clinical trials 
for pediatric forms of brain tumors [86]. It has been demonstrated that some MB 
tumors express VEGFR [68, 87]. 
Sorafenib is a multi-kinase inhibitor presently approved for use in renal cell cancer and 
liver cancer [88].  This drug is undergoing clinical trials for medulloblastoma and other 
types of pediatric brain tumors [89]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Some of the cell signalling pathways involved in MB development 
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1.6.2.4   NOTCH 
 
During cerebellar development Notch signalling plays an important role, different 
members of this family are involved in GCP expansion [9]. 
Notch deregulation has been shown to result in brain tumor development [21, 90]. Notch 
signalling promotes medulloblastoma stem like cell survival, and Notch it’s over express 
in medulloblastoma [91, 92]. 
 
 
1.6.2.5 TGFf3 
 
Recently, research has linked the canonical TGFf3 pathway to the pathogenesis of 
medulloblastoma. The transforming growth factor beta (TGFf3) was found by Aref et. 
al. to be a potential contributor to medulloblastoma progression and metastasis [93]. 
Previous research had described the involvement of this pathway in the physiological 
and pathophysiological processes of the normal brain and investigators observed 
resistance to growth inhibitors in glioma cell was linked to growth receptors [18]. It 
has also been described by Subkhankulova et. al. that there is difference in expression 
of a number of genes involved in the TGFf3 pathway [94]. 
TGFf3 in normal tissue is secreted by platelets in cancer is secreted by surrounding 
environment and is overexpressed, its secretion serves as a signal for the cancer cells 
proliferation, which ha been indicated by Aref et. al. [93, 95]. 
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2 AIMS OF THE THESIS 
 
 
The present thesis was aimed to investigate the effects of epigenetic drugs as 
monotherapy and in combination with tyrosine kinase inhibitors on the growth of brain 
tumor cells. 
The main rationales are: 
 
1.   To find new therapeutic modalities for the therapy of medulloblastoma with the 
use of epigenetic drugs in combination with tyrosine kinase inhibitors. 
 
2.   To acquire a better understanding of the epigenetic markers involved in the 
silencing of key genes of the apoptotic pathways. 
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3 RESULTS 
 
 
3.1   EFFECTS OF EPIGENETIC MODIFIERS AND TYROSINE KINASE 
INHIBITORS ON MEDULLOBLASTOMA CELL GROWTH 
 
 
3.1.1   Paper 1 
 
The rationale for this was to achieve enhanced cytotoxic effects by combining  4-PB 
with gefitinib or vandetanib  two receptor tyrosine kinase inhibitors,  using a 
medulloblastoma cell line (DAOY)  and a glioblastoma multiforme  cell line 
(U343MGa).  The cytotoxic effects using 4-PB in combination with gefitinib or 
vandetanib  showed increase cell death, and clonogenic assays showed a loss in the 
ability for colony formation.  These result suggested that a combined treatement with 
the HDACi 4-PB and RTKi may be beneficial in the treatment  of brain tumors. 
 
 
3.1.2   Manuscript 
 
 
 
 
HO 
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Sodium 4-Phenylbutyrate 5-aza-2 'deoxicytidine 
 
 
 
Figure 7 Molecular structures 4-PB and decitabine 
 
Based on the results obtained in paper I, we decided to expand the repertoire of tyrosine 
kinase inhibitors to include imatinib and sorafenib, two inhibitors that have been widely 
used in the treatment  of different cancers and is currently undergoing  clinical trials for 
pediatric brain tumors.   The epigenetic  modifiers, 4-BP and 5-Aza-dC had minor 
effects on medulloblastoma cell growth when used as single agents. However, 
combining these drugs with the small molecule inhibitors of tyrosine kinases, imatinib 
and sorafenib, significantly  enhanced the medulloblastoma cell cytotoxicity. 
We also observed an arrest in subG1 after therapy that correlates with the increase in 
apoptosis that was observed after we carried out a cell cycle study and a caspase 3/7 
activity assay. 
The epigenetic  assays showed a difference in methylation  and HDAC activity after 
triple therapy that can as well be correlated to increase cell death and an arrest in 
subG1.  After we investigated the expression of key genes in non-treated  cells and triple 
treated cells we as well observed a difference in their expression  levels that could be 
used to explain the enhanced cell death and increase in apoptosis. 
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Figure 8 Molecular structures of Imatinib and Sorafenib 
 
 
 
The use of epigenetic  modificators  and tyrosine kinase inhibitors are therefore a good 
alternative for the treatment of medulloblastoma. The combination as we have shown 
will activate caspases 3/7 and decrease the expression  of anti-apoptotic genes as we 
have as well demonstrated. 
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4  DISCUSSION AND FUTURE PERSPECTIVES 
 
 
4.1   THESIS DISCUSSION 
 
Our results shows that a combination therapy using HDAC inhibitors together with 
receptor tyrosine kinases should be further evaluated as a treatment option for adult and 
pediatric brain tumors (Paper 1). 
 
Results after the incorporation of 5-aza-dc resulted in enhanced cell killing after 
combination of the two epigenetic drugs, and using lower dosages of the drugs after 
triple combination. These results suggest that DNMTs play a role in MB progression, 
and are involved in inhibition of apoptosis together with HDACs. Their inhibition has 
led to enhance cell death by sensitization of MB cells. Further studies of the cell cycle 
showed increase number of cells in sub-G1 and increase activity of caspases 3/7. Our 
conclusion is that the epigenetic modifiers might restored the expression of genes 
involved in the induction of apoptosis and cell cycle activity, therefore  enhancing cell 
death when imatinib or sorafenib are added. The epigenetic modifiers may sensitize 
medulloblastoma cells to  tyrosine kinase inhibitors resulting in increased cell death. 
We showed in the manuscript that HDAC1 mRNA expression was reduced after triple 
treatment and HDAC1 has been pointed to be involved in drug resistance [49, 96]. 
 
These studies indicates the importance of epigenetics in drug resistance due to silencing 
of genes important in the regulation of cell proliferation and apoptosis. After the use of 
4-PB in the triple treatment we showed the down regulation of Bcl-2 an anti-apoptotic 
member of the BCL2 family. Others have previously reported that HDACis down 
regulated the expression of BCL2 family members [97]. 
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4.2   FUTURE PERSPECTIVES 
 
 
•  All our studies were conducted in vitro therefore it is of great importance to 
conduct an in vivo investigation of our findings. In vivo models will indicate if 
our findings are relevant and will also allow us to get a better knowledge of 
mechanisms involved in drug resistance. This will be madatory in order to 
transfer these potential new drug combinations into clinical trials. 
 
•  We are planning to investigate novel receptor tyrosine kinases that together 
with epigenetic modifiers might result in enhance cell death. At the same time 
we are planning to screen novel HDAC and DNMT inhibitors not only for 
medulloblastoma therapy but also for other forms of aggressive pediatric brain 
tumors. 
 
•  To further study the effects of these combination of drugs, more molecular 
analysis on the mechanisms of action of these drugs used in combination will 
need to be performed. These will include analysis of important pro-/-anti- 
apoptotic genes and the expression analysis in genes involved in cell cell cycle 
progression. 
 
•  Since most patient with medulloblastoma and other malignat brain tumors ar 
subjected to radiation therapy. The drug combinations used in this study should 
be investigated together with different modes of radiation therapy. 
20 
 
 
21  
 
 
 
 
 
 
 
5  ACKNOWLEDGEMENTS 
I will first like to thank all the people that help me during all these years gave me 
advise and guide. 
 
I would like to thank my supervisor Arne Ostman for all the help and support, for all 
the advice, for opening the doors of his lab to me and for accepting the duty of 
becoming main supervisor. Thanks for been an excellent supervisor and for all your 
patience and understanding. 
 
I would also like to thank my co-supervisor John Inge Johnsen for his help and advice 
about medulloblastoma, for all the time revising results, and for allowing me to work in 
his lab. Thanks for been a great guide and for all the support. 
 
Would like to thank Per Kogner, for his kindness and for allowing me to work at his lab 
in CCK. 
 
I need to thank Tomas Ekstrom for making this all the help and teaching me about 
epigenetics and for making licenciature possible. 
 
Now I need to thank Lotta  for all the help in the lab, and cell culturing, without your 
help it would have been very tuft. Thanks to all the girls in the group Agnes for 
listening and giving advice hope all will go great for you and the new baby; Jelena  for 
all your guidance, kindness and for the advice hope your project will develop fine and 
to see you maybe in Boston, Mallin for the advice about clonogenic assays wish you all 
the best, Ceci the lab and fitness instructor all the best, Anna K the singing PhD always 
happy and kind thanks and all the best for you as well. 
 
To Bertha Brodin for your time and guidance, for been there and giving me great 
advice. For all the help!!! Wish you all the best and hope we will stay friends. Gracias 
port u Amistad y port tu ayuda no solo en cuanto a experimentos pero tambien como 
amiga. 
 
To my good friends Luqman my serious Kurdish friend and Andrii for all the laughs I 
still remember when you first started at CLs group “great days”, thanks to both of you 
for the great moments, and support during difficult times. 
 
I would like to thank Catharina Larsson for all the help you gave me, without you this 
would not have been possible. 
 
To my wise friend Weng-Ong Lui for having a big heart and been a great friend, hope 
our friendship will last forever. Best of luck, I am sure one day you will be a great 
Professor. 
 
To all my colleagues at Catharina Larsson and Wen-Ong Luis group, Omid the quiet, 
smart boy thanks for the help; to Hong the “bad Girl” my Chinese friend wish you all 
the best; Andrew…. there are no words, thanks for all; Nimrod  the tuft Mr. X friend 
22 
 
 
 
 
 
 
 
thanks for the laughs and good times at CMM; of course Dr, Dr Christopher Julin 
Mr. X himself for all those happy memories and the wise advice; Stefano che posso 
dire sei un grande amico e una grande persona…grazie di tutto hope we stay friends; 
To wise Dr Felix best of lucks; wow can I not thank the crazy greek Dr Anastasios 
thanks for all the help, the laughs those great moments at CMM together with all the 
gang, for been a great friend, all the best; to the now big shot Dr Fukakis thanks for all 
the help and for those great talks about the “Roman Empire”; Adam the young doctor to 
be, wish you all the best; Pinar, and Na Good luck and all the best. 
 
My friends and Colleagues at Arne Ostman group to my german good friend Dr 
Martin Augsten thanks for the great times and sorry for Germany loosing against 
Italy, better times will come, all the best to you; Markus the crazy scientist and 
photographer thanks for the fun talks and wish you the best of lucks, I am sure you will 
become a great PI; Jeroen the kind quite boy, thanks for all the help, hope all will go 
great for you; thanks to the rest of the team. 
 
My Iranian friends the IBB guys, his majesty Pedram the first thanks for the laughs 
and good times, for the scientific advice and for offering the services of the IBB in case 
there was a need; Ali former president of the IBB thanks for been a good friend wish 
you all the best: Reza soon you will become Italian thanks for the good moments; 
Amir thanks for your friend ship wish you all the best. The young Iranian boys “bad” 
Madhy  hope all will go fine with you and that you will soon publish in Nature  ;) ; 
Hanif thanks for your help and kindness wish you the best in your PhD I am sure you 
will do great. 
 
To my friends at Gunnar Norsdet group; Mathias wish you all the best thanks for all the 
help; crazy Fahad thanks for making life fun and bringing a smile to my face, hope we 
stay friend, good luck in your new life in Oman; Anenisia my kind Brazilian friend 
wish you all the best in your new life as a doctor in Brazil; Yin-Choy my Malaysian 
friend I am sure you will be a great professor, best of lucks. 
 
Previous colleagues at CMM Simone P; Michela B; Mohsen Karimi, and to Atosa 
will like to wish all the best and thank for the great moments. 
 
To professor Manuel Patarroyo thanks for the help and teaching me about the 
extracellular matrix, integrins and laminins. 
 
To all the members of the choir of the catholic cathedral in Stockholm, Elisabeth, 
Anja, Percy, Reiner,  Rossine and all the rest, thanks for the beautifull moments and 
happiness you brought to my life. To Ingeborg Van der Plog for her help and advice. 
 
To my Ukranian friend Dmytro Unukovych whish you all the best in your career as an 
MD thanks for the great talks and advice. 
 
To all my colleagues in floor 00 of CCK: Barry W; crazy bad boy Ruko.  Wish you all 
the best, thanks for the good times. 
23  
 
 
 
 
 
 
To a great friend without him this project would not have been possible Ninib B, 
thanks for all the advice and help, but most of all thanks for your friendship. Wish you 
all the best from the bottom of my heart. I am sure one day you will become a big shot 
group leader, i feel lucky to have you as a friend. 
 
To my friends Orlando, Jorma and Noemi for making life outside the lab fun for the 
laughts advice great parties and fantastic moments. To Sandra Augsten thanks for the 
good laughs and good luck. 
 
To John  Steen for all his help and advice, for his time and guidance. 
 
To Robert Harris, thanks for the guidance, advice and help. To everyone at the 
department of CNS, thanks for all the help and making this Licenciature possible. 
 
To my Mother for been there for me whenever I needed; for your love and support; for 
teaching me the value of life; for your understanding, and for been a great mother, love 
you very much. 
 
To my brother and his family, thanks for having been there in the difficult moments I 
went through; to my aunt Maria Del Carmen thanks for been like an older sister to 
me, for listening to my worries and giving me advice, and to all my relatives in Italy, 
Colombia and Venezuela. 
 
To my doctors at Dana Farber Dr Stephen  Sallan; Dr Holcombe E Grier, and my 
collaborators Dr Scott L Pomeroy and Dr Mark W Kieran; to all my doctors at 
Brighams and Women Hospital Dr Ian Dunn, Dr Catherson, and Dr Scott Solomon, 
thanks for all you did for me;  my doctor and mentor at Stanford Medical Center Dr 
Michael P. Link, and 21st Oncology Center in Florida Dr Isaac Vaisman. Thanks for 
all the help and guidance, for been there when I needed you the most.  For your patience 
and support. You all have been and are my inspiration, you are the force that has lead 
me to where I am today. 
 
To all of you that I have not name in but that are present in my memory, and to all my 
friends all over the world. THANKS!!! 
24 
 
 
 
 
 
 
 
 
6  REFERENCES 
 
 
1. Huse, J.T. and E.C. Holland, Targeting brain cancer: advances in the 
molecular pathology of malignant glioma and medulloblastoma. Nat Rev 
Cancer, 2010. 10(5): p. 319-31. 
2. Chandana, S.R., et al., Primary brain tumors in adults. Am Fam Physician, 
2008. 77(10): p. 1423-30. 
3. Ricard, D., et al., Primary brain tumours in adults. Lancet, 2012. 379(9830): p. 
1984-96. 
4. Fleming, A.J. and S.N. Chi, Brain tumors in children. Curr Probl Pediatr 
Adolesc Health Care, 2012. 42(4): p. 80-103. 
5. Heath, J.A., S. Zacharoulis, and M.W. Kieran, Pediatric neuro-oncology: 
Current status and future directions. Asia Pac J Clin Oncol, 2012. 8(3): p. 223- 
31. 
6. Thompson, M.C., et al., Genomics identifies medulloblastoma subgroups that 
are enriched for specific genetic alterations.  J Clin Oncol, 2006. 24(12): p. 
1924-31. 
7. Leary, S.E. and J.M. Olson, The molecular classification of medulloblastoma: 
driving the next generation clinical trials. Curr Opin Pediatr, 2012. 24(1): p. 33- 
9. 
8. Sadighi, Z., T. Vats, and S. Khatua, Childhood medulloblastoma: the paradigm 
shift in molecular stratification and treatment profile. J Child Neurol, 2012. 
27(10): p. 1302-7. 
9. Hatten, M.E. and M.F. Roussel, Development and cancer of the cerebellum. 
Trends Neurosci, 2011. 34(3): p. 134-42. 
10. Schuller, U., et al., Acquisition of granule neuron precursor  identity is a critical 
determinant of progenitor cell competence to form Shh-induced 
medulloblastoma. Cancer Cell, 2008. 14(2): p. 123-34. 
11. Yang, Z.J., et al., Medulloblastoma can be initiated by deletion of Patched in 
lineage-restricted progenitors or stem cells. Cancer Cell, 2008. 14(2): p. 135- 
45. 
12. Read, T.A., et al., Identification of CD15 as a marker for tumor-propagating 
cells in a mouse model of medulloblastoma. Cancer Cell, 2009. 15(2): p. 135- 
47. 
13. Gibson, P., et al., Subtypes of medulloblastoma have distinct developmental 
origins. Nature, 2010. 468(7327): p. 1095-9. 
14. Kawauchi, D., et al., A mouse model of the most aggressive subgroup of human 
medulloblastoma. Cancer Cell, 2012. 21(2): p. 168-80. 
15. Pei, Y., et al., An animal model of MYC-driven medulloblastoma. Cancer Cell, 
2012. 21(2): p. 155-67. 
16. Lee, C.J., W.I. Chan, and P.J. Scotting, CIC, a gene involved in cerebellar 
development and ErbB signaling, is significantly expressed in 
medulloblastomas. J Neurooncol, 2005. 73(2): p. 101-8. 
17. Marino, S., Medulloblastoma: developmental mechanisms out of control. 
Trends Mol Med, 2005. 11(1): p. 17-22. 
18. Rodini, C.O., et al., Aberrant signaling pathways in medulloblastomas: a stem 
cell connection. Arq Neuropsiquiatr, 2010. 68(6): p. 947-52. 
19. Taylor, M.D., et al., Molecular subgroups of medulloblastoma: the current 
consensus. Acta Neuropathol, 2012. 123(4): p. 465-72. 
20. Vaillant, C. and D. Monard, SHH pathway and cerebellar development. 
Cerebellum, 2009. 8(3): p. 291-301. 
21. Roussel, M.F. and M.E. Hatten, Cerebellum development and medulloblastoma. 
Curr Top Dev Biol, 2011. 94: p. 235-82. 
22. Behesti, H. and S. Marino, Cerebellar granule cells: insights into proliferation, 
differentiation, and role in medulloblastoma pathogenesis. Int J Biochem Cell 
Biol, 2009. 41(3): p. 435-45. 
25  
 
 
 
 
 
 
23. Srivastava, V.K. and J. Nalbantoglu, The cellular and developmental biology of 
medulloblastoma: current perspectives on experimental therapeutics. Cancer 
Biol Ther, 2010. 9(11): p. 843-52. 
24. Northcott, P.A., et al., Molecular subgroups of medulloblastoma. Expert Rev 
Neurother, 2012. 12(7): p. 871-84. 
25. Robinson, G., et al., Novel mutations target distinct subgroups of 
medulloblastoma. Nature, 2012. 488(7409): p. 43-8. 
26. Northcott, P.A., et al., Medulloblastoma comprises four distinct molecular 
variants. J Clin Oncol, 2011. 29(11): p. 1408-14. 
27. Kool, M., et al., Molecular subgroups of medulloblastoma: an international 
meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, 
SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol, 2012. 
123(4): p. 473-84. 
28. Biel, M., V. Wascholowski, and A. Giannis, Epigenetics--an epicenter of gene 
regulation: histones and histone-modifying enzymes. Angew Chem Int Ed Engl, 
2005. 44(21): p. 3186-216. 
29. Smith, L.T., G.A. Otterson, and C. Plass, Unraveling the epigenetic code of 
cancer for therapy. Trends Genet, 2007. 23(9): p. 449-56. 
30. Lindsey, J.C., et al., Epigenetic events in medulloblastoma development. 
Neurosurg Focus, 2005. 19(5): p. E10. 
31. Toyota, M., et al., Cancer epigenomics: implications of DNA methylation in 
personalized cancer therapy. Cancer Sci, 2009. 100(5): p. 787-91. 
32. Pugh, T.J., et al., Medulloblastoma exome sequencing uncovers subtype-specific 
somatic mutations. Nature, 2012. 488(7409): p. 106-10. 
33. Ramaswamy, V., P.A. Northcott, and M.D. Taylor, FISH and chips: the recipe 
for improved prognostication  and outcomes for children with medulloblastoma. 
Cancer Genet, 2011. 204(11): p. 577-88. 
34. Parsons, D.W., et al., The genetic landscape of the childhood cancer 
medulloblastoma. Science, 2011. 331(6016): p. 435-9. 
35. Manoranjan, B., et al., Medulloblastoma stem cells: where development and 
cancer cross pathways. Pediatr Res, 2012. 71(4 Pt 2): p. 516-22. 
36. Packer, R.J. and G. Vezina, Management of and prognosis with 
medulloblastoma: therapy at a crossroads.  Arch Neurol, 2008. 65(11): p. 1419- 
24. 
37. Hargrave, D.R. and S. Zacharoulis, Pediatric CNS tumors: current treatment 
and future directions. Expert Rev Neurother, 2007. 7(8): p. 1029-42. 
38. Klesse, L.J. and D.C. Bowers, Childhood medulloblastoma: current status of 
biology and treatment. CNS Drugs, 2010. 24(4): p. 285-301. 
39. Mueller, S. and S. Chang, Pediatric brain tumors: current treatment strategies 
and future therapeutic approaches.  Neurotherapeutics, 2009. 6(3): p. 570-86. 
40. Fossati, P., U. Ricardi, and R. Orecchia, Pediatric medulloblastoma: toxicity of 
current treatment and potential role of protontherapy. Cancer Treat Rev, 2009. 
35(1): p. 79-96. 
41. Balch, C., et al., New anti-cancer strategies: epigenetic therapies and 
biomarkers. Front Biosci, 2005. 10: p. 1897-931. 
42. Johnsen, J.I., et al., Embryonal neural tumours and cell death. Apoptosis, 2009. 
14(4): p. 424-38. 
43. Natsume, A., et al., Epigenetic aberrations and therapeutic implications in 
gliomas. Cancer Sci, 2010. 101(6): p. 1331-6. 
44. Rood, B.R., H. Zhang, and P.H. Cogen, Intercellular  heterogeneity of 
expression of the MGMT DNA repair gene in pediatric medulloblastoma. 
Neuro Oncol, 2004. 6(3): p. 200-7. 
45. Faoro, D., et al., Expression of O(6)-methylguanine-DNA methyltransferase in 
childhood medulloblastoma. J Neurooncol, 2011. 103(1): p. 59-69. 
46. Hrebackova, J., J. Hrabeta, and T. Eckschlager, Valproic acid in the complex 
therapy of malignant tumors. Curr Drug Targets, 2010. 11(3): p. 361-79. 
47. Fruhwald, M.C. and O. Witt, The epigenetics of cancer in children. Klin 
Padiatr, 2008. 220(6): p. 333-41. 
48. Ma, X., H.H. Ezzeldin, and R.B. Diasio, Histone deacetylase inhibitors: current 
status and overview of recent clinical trials. Drugs, 2009. 69(14): p. 1911-34. 
26 
 
 
 
 
 
 
 
49. Witt, O., et al., HDAC family: What are the cancer relevant targets? Cancer 
Lett, 2009. 277(1): p. 8-21. 
50. Hoshino, I. and H. Matsubara, Recent advances in histone deacetylase targeted 
cancer therapy. Surg Today, 2010. 40(9): p. 809-15. 
51. Rosato, R.R., et al., Simultaneous activation of the intrinsic and extrinsic 
pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor- 
related apoptosis-inducing ligand (TRAIL) synergistically induces 
mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer 
Ther, 2003. 2(12): p. 1273-84. 
52. Carew, J.S., F.J. Giles, and S.T. Nawrocki, Histone deacetylase inhibitors: 
mechanisms of cell death and promise in combination cancer therapy. Cancer 
Lett, 2008. 269(1): p. 7-17. 
53. Li, X.N., et al., Phenylbutyrate and phenylacetate induce differentiation and 
inhibit proliferation of human medulloblastoma cells. Clin Cancer Res, 2004. 
10(3): p. 1150-9. 
54. Iannitti, T. and B. Palmieri, Clinical and experimental applications of sodium 
phenylbutyrate. Drugs R D, 2011. 11(3): p. 227-49. 
55. Perego, P., et al., Sensitization of tumor cells by targeting histone deacetylases. 
Biochem Pharmacol, 2012. 83(8): p. 987-94. 
56. Thurn, K.T., et al., Rational therapeutic combinations with histone deacetylase 
inhibitors for the treatment of cancer. Future Oncol, 2011. 7(2): p. 263-83. 
57. Miller, C.P., et al., Therapeutic strategies to enhance the anticancer  efficacy of 
histone deacetylase inhibitors. J Biomed Biotechnol, 2011. 2011: p. 514261. 
58. Peng, L. and E. Seto, Deacetylation of nonhistone proteins by HDACs and the 
implications in cancer. Handb Exp Pharmacol, 2011. 206: p. 39-56. 
59. Popovic, R. and J.D. Licht, Emerging epigenetic targets and therapies in 
cancer medicine. Cancer Discov, 2012. 2(5): p. 405-13. 
60. Rodriguez-Paredes, M. and M. Esteller, Cancer epigenetics reaches 
mainstream oncology. Nat Med, 2011. 17(3): p. 330-9. 
61. Cowan, L.A., S. Talwar, and A.S. Yang, Will DNA methylation inhibitors work 
in solid tumors? A review of the clinical experience with azacitidine and 
decitabine in solid tumors. Epigenomics, 2010. 2(1): p. 71-86. 
62. Gros, C., et al., DNA methylation inhibitors in cancer: Recent and future 
approaches.  Biochimie, 2012. 94(11): p. 2280-96. 
63. Foulks, J.M., et al., Epigenetic drug discovery: targeting DNA 
methyltransferases. J Biomol Screen, 2012. 17(1): p. 2-17. 
64. Song, S.H., S.W. Han, and Y.J. Bang, Epigenetic-based therapies in cancer: 
progress to date. Drugs, 2011. 71(18): p. 2391-403. 
65. Fahy, J., A. Jeltsch, and P.B. Arimondo, DNA methyltransferase inhibitors in 
cancer: a chemical and therapeutic patent overview and selected clinical 
studies. Expert Opin Ther Pat, 2012. 
66. Li, K.K., et al., DNA Methylation as a Target of Epigenetic Therapeutics in 
Cancer. Anticancer Agents Med Chem, 2012. 
67. Rossig, C., H. Juergens, and W.E. Berdel, New targets and targeted drugs for 
the treatment of cancer: an outlook to pediatric oncology. Pediatr Hematol 
Oncol, 2011. 28(7): p. 539-55. 
68. Nageswara Rao, A.A., et al., Biologically targeted therapeutics in pediatric 
brain tumors. Pediatr Neurol, 2012. 46(4): p. 203-11. 
69. Gilbertson, R.J., et al., Prognostic significance of HER2 and HER4 
coexpression in childhood medulloblastoma. Cancer Res, 1997. 57(15): p. 
3272-80. 
70. K, E.W., Molecularly targeted therapy for pediatric brain tumors. J 
Neurooncol, 2005. 75(3): p. 335-43. 
71. Gilbertson, R.J., Medulloblastoma: signalling a change in treatment. Lancet 
Oncol, 2004. 5(4): p. 209-18. 
72. Bal, M.M., et al., Does c-erbB-2 expression have a role in medulloblastoma 
prognosis? Indian J Pathol Microbiol, 2006. 49(4): p. 535-9. 
73. Gajjar, A., et al., Clinical, histopathologic, and molecular markers of 
prognosis: toward a new disease risk stratification system for medulloblastoma. 
J Clin Oncol, 2004. 22(6): p. 984-93. 
27  
 
 
 
 
 
 
74. Wlodarski, P.K. and J. Jozwiak, Therapeutic targets for medulloblastoma. 
Expert Opin Ther Targets, 2008. 12(4): p. 449-61. 
75. Jansen, M.H., et al., Diffuse intrinsic pontine gliomas: a systematic update on 
clinical trials and biology. Cancer Treat Rev, 2012. 38(1): p. 27-35. 
76. Pollack, I.F., et al., A phase II study of gefitinib and irradiation in children with 
newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor 
Consortium. Neuro Oncol, 2011. 13(3): p. 290-7. 
77. Freeman, B.B., 3rd, et al., Evaluation of gefitinib for treatment of refractory 
solid tumors and central nervous system malignancies in pediatric patients. 
Cancer Invest, 2006. 24(3): p. 310-7. 
78. Gilbertson, R.J., et al., Mutational analysis of PDGFR-RAS/MAPK pathway 
activation in childhood medulloblastoma. Eur J Cancer, 2006. 42(5): p. 646-9. 
79. Ostman, A. and C.H. Heldin, PDGF receptors as targets in tumor treatment. 
Adv Cancer Res, 2007. 97: p. 247-74. 
80. Andrae, J., et al., Platelet-derived growth factor-B and -C and active alpha- 
receptors in medulloblastoma cells. Biochem Biophys Res Commun, 2002. 
296(3): p. 604-11. 
81. MacDonald, T.J., et al., Expression profiling of medulloblastoma: PDGFRA 
and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat 
Genet, 2001. 29(2): p. 143-52. 
82. Gilbertson, R.J. and S.C. Clifford, PDGFRB is overexpressed in metastatic 
medulloblastoma. Nat Genet, 2003. 35(3): p. 197-8. 
83. Gottardo, N.G. and A. Gajjar, Current therapy for medulloblastoma. Curr Treat 
Options Neurol, 2006. 8(4): p. 319-34. 
84. Duffaud, F. and A. Le Cesne, Imatinib in the treatment of solid tumours. Target 
Oncol, 2009. 4(1): p. 45-56. 
85. Enguita-German, M., et al., KIT expression and methylation in 
medulloblastoma and PNET cell lines and tumors. J Neurooncol, 2011. 103(2): 
p. 247-53. 
86. Kieran, M.W., et al., Phase I study of SU5416, a small molecule inhibitor of the 
vascular endothelial growth factor receptor (VEGFR) in refractory pediatric 
central nervous system tumors. Pediatr Blood Cancer, 2009. 52(2): p. 169-76. 
87. Slongo, M.L., et al., Functional VEGF and VEGF receptors are expressed in 
human medulloblastomas. Neuro Oncol, 2007. 9(4): p. 384-92. 
88. Ibrahim, N., et al., Molecular targeted therapies for cancer: sorafenib mono- 
therapy and its combination with other therapies (review). Oncol Rep, 2012. 
27(5): p. 1303-11. 
89. Wolff, J.E., et al., Preliminary experience with personalized and targeted 
therapy for pediatric brain tumors. Pediatr Blood Cancer, 2012. 59(1): p. 27- 
33. 
90. Stockhausen, M.T., K. Kristoffersen, and H.S. Poulsen, Notch signaling and 
brain tumors. Adv Exp Med Biol, 2012. 727: p. 289-304. 
91. Pierfelice, T.J., et al., Notch, neural stem cells, and brain tumors. Cold Spring 
Harb Symp Quant Biol, 2008. 73: p. 367-75. 
92. Zweidler-McKay, P.A., Notch signaling in pediatric malignancies. Curr Oncol 
Rep, 2008. 10(6): p. 459-68. 
93. Aref, D., et al., Canonical TGF-beta Pathway Activity Is a Predictor of SHH- 
Driven Medulloblastoma Survival and Delineates Putative Precursors in 
Cerebellar Development. Brain Pathol, 2012. 
94. Subkhankulova, T., et al., Bmi1 directly represses p21Waf1/Cip1 in Shh- 
induced proliferation of cerebellar  granule cell progenitors. Mol Cell Neurosci, 
2010. 45(2): p. 151-62. 
95. Byrd, T., R.G. Grossman, and N. Ahmed, Medulloblastoma-biology and 
microenvironment: a review. Pediatr Hematol Oncol, 2012. 29(6): p. 495-506. 
96. Xu, Y., et al., Role for Class I histone deacetylases in multidrug resistance. Exp 
Cell Res, 2012. 318(3): p. 177-86. 
97. Spiegel, S., S. Milstien, and S. Grant, Endogenous modulators and 
pharmacological inhibitors of histone deacetylases in cancer therapy. 
Oncogene, 2012. 31(5): p. 537-51. 
  
 
